Trial Profile
A Phase 2 Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Anaplastic large cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Seagen; Seattle Genetics
- 15 May 2020 According to a Takeda China media release, ADCETRIS (brentuximab vedotin) has been officially approved by Chinas National Medical Products Administration (NMPA) for use in adult patients with relapsed or refractory systemic Anaplastic Large Cell Lymphoma (sALCL) or CD30-positive Hodgkin Lymphoma. The local approval of ADCETRIS in China is based on the data from clinical studies SG035-0004, SG035-0003 and C25007.
- 13 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 29 Jan 2018 Results (n=380) of pooled data from six trials assessing population pk and exposure-response relationships for the antibody-drug conjugate brentuximab vedotin in ctcl patients, were published in the Clinical Pharmacology and Therapeutics.